Avalo Therapeutics Inc AVTX 深 沪
等待开盘 08-11 09:30:00 美东时间
19.23
+0.910
+4.97%
华盛通- 最 高19.275
- 今 开18.25
- 成交量 32.81万股
- 最 低 18.00
- 昨 收 18.32
- 总市值 10.17亿
- 52周最高 24.27
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 8.41
- 委 比 -90.19%
- 总股本 5290.30万
- 历史最高 22032.00
- 量 比 0.76
- 振 幅 6.96%
- 历史最低 3.39
- 每 手 1
- 风险率 3.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
08-07 19:07
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share from the same period last year.
08-06 19:46
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38
Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.
07-06 20:11
Avalo Therapeutics To Be Added To Small-Cap Russell 2000 Index And Broad-Market Russell 3000 Index, Effective June 26
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 300...
06-26 19:01
美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35
B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.
06-12 17:54
